# LYNPARZA® (olaparib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/olaparib

> The FDA approved LYNPARZA® (olaparib), sponsored by ASTRAZENECA PLC (AZN), on August 17, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LYNPARZA® (olaparib) |
| Codes | MK-7339, AZD2281, KU-0059436 |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | [Ovarian Cancer](https://sec-api.dev/indications/ovarian-cancer), [Advanced Solid Neoplasms](https://sec-api.dev/indications/advanced-solid-neoplasms) |
| Modality | small_molecule |
| FDA designations | accelerated, priority review |

## Timeline

### August 17, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170817, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### May 8, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20200508, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### May 19, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20200519, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### December 7, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20201207, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### March 11, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority STANDARD; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### January 31, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### March 11, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220311, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### August 26, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20220826, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### April 28, 2023: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The committee will discuss supplemental new drug application (sNDA) 208558/S–025, for LYNPARZA (olaparib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for this product is in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)." https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-28-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04282023
- FDA advisory committee calendar: "VOTE: As FDA reviews the proposed indication for olaparib in combination with abiraterone for initial treatment of mCRPC, should the indication be restricted to patients whose tumors have a BRCA mutation? If you feel the combination should not be approved for any indication, please abstain from voting and explain your thinking regarding approvability during the post-voting discussion period. Vote Result: Yes: 11 No: 1 Abstain: 1" https://www.fda.gov/media/169632/download

### May 31, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230531, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### November 6, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208558 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20231106, review_priority STANDARD; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22

### August 12, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Advanced Solid Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03742895 (Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-14." https://clinicaltrials.gov/study/NCT03742895

### July 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Ovarian Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04884360 (D9319C00001- 1L OC Mono Global RCT): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04884360

### August 14, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Advanced Solid Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03742895 (Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-14." https://clinicaltrials.gov/study/NCT03742895?tab=results

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ovarian Cancer; Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04421963 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04421963

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ovarian Cancer; Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04421963 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04421963

## Same indication

- [INCB123667](https://sec-api.dev/pdufa/incb123667) (INCY)
- [Luveltamab tazevibulin](https://sec-api.dev/pdufa/luveltamab-tazevibulin) (STRO)
- [Mirvetuximab soravtansine](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) (ABBV)
- [Mirvetuximab soravtansine plus bevacizumab](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab) (ABBV)
- [Pamiparib capsule](https://sec-api.dev/pdufa/pamiparib) (ONC)
- [REGN10597](https://sec-api.dev/pdufa/regn10597) (REGN)
- [Lifyorli™ (relacorilant)](https://sec-api.dev/pdufa/relacorilant) (CORT)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Vudalimab](https://sec-api.dev/pdufa/vudalimab) (XNCR)

Calendar months: [July 2026](https://sec-api.dev/fda-calendar/2026-07), [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/olaparib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LYNPARZA® (olaparib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/olaparib

```bibtex
@misc{secapidev_pdufa_olaparib_20261116,
  title        = {LYNPARZA® (olaparib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/olaparib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_olaparib_20261116","title":"LYNPARZA® (olaparib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/olaparib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
